Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

PhosAgro reports for 3 months of 2024 by RAS

4/26/24 PHOR

Phosagro reports for 2023 by IFRS

4/26/24 PHOR

TNS Energy Mari El reported for 3 months of 2024 by RAS

4/26/24 MISB

O'Key's Q1 revenue grew by 7.2%

4/26/24 OKEY

Board of Directors of Kuznetskiy Bank recommended that dividends be paid for 2023

4/26/24 KUZB

Moscow Exchange shareholders to decide on dividends on May 31

4/26/24 MOEX

Seligdar found a way to improve Kuchus' performance

4/26/24 SELG

Lukoil reports for 3 months of 2024 by RAS

4/26/24 LKOH

Cian has reported for 2023

4/26/24 CIAN

Ingrad reported for 2023 by IFRS

4/26/24 INGR